RNAC
Cartesian TherapeuticsANasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
+
Peers tracked
10
U.S. public peers
Grade Position
Above peers
vs peer average
RNAC vs peer average
80/100
RNAC vs. peer average (A vs. C)
Grade spread
A 3 · C 3 · D 3 · F 1
Graded peers loaded
Coverage
10 graded
100% of tracked
Peer overview
CABA is the first available peer comparator.
Thematic autoimmune cell-therapy comparator, but not a direct operating or valuation peer because its lead approach is CD19-directed while RNAC is developing an autologous BCMA mRNA CAR-T program.
✓Peer source comes from the stored AI memo or peer model
✓Grades and factor rows use RankAlpha API data when available
✓Missing peer scores remain blank instead of being estimated
✓Side-by-side comparison keeps the data contract visible
RNAC
Cartesian Therapeutics
CABA
Cabaletta Bio
Grade
A
D
Momentum
77
64
Value
41
41
Sentiment
84
51
Setup Bias
Net —
-
Market Cap
-
-
Posture
Constructive
Defensive
Grade position vs CABA
RNAC / CABA
Grade Position
Above peers
RNAC vs. peer average (A vs. C)
80/100
Momentum
77
RNACValue
41
RNACSentiment
84
RNACRotation landscape
Peers ranked by the order returned from the peer source, with grades from the API.
Rank
Ticker
Company
Grade
Grade score
vs RNAC
CABA is the first peer returned for this comparison set.